AIRO2023

BOLOGNA, 27-29 OTTOBRE 2023

PALAZZO DEI CONGRESSI

Radioterapia Oncologica: l'evoluzione al servizio dei pazienti





BOLOGNA, 27-29 OTTOBRE 2023 PALAZZO DEI CONGRESSI

Radioterapia Oncologica: l'evoluzione al servizio dei pazienti

mpMRI SENSITIVITY IN DETECTING MACROSCOPIC LOCAL RECURRENCES IN PROSTATE CANCER PATIENTS WITH PLANNED SALVAGE RADIOTHERAPY: UPDATED RESULTS OF AN OBSERVATIONAL STUDY.

SENSIBILITÀ DELLA RMN MULTI-PARAMETRICA NELLA DIAGNOSI DI RECIDIVA LOCALE MACROSCOPICA IN PAZIENTI CON CARCINOMA PROSTATICO AVVIATI A RADIOTERAPIA DI SALVATAGGIO: RISULTATI AGGIORNATI DI UNO STUDIO OSSERVAZIONALE

Letizia Cavallini

Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria; Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum



AIRO2023

Aim

- Biochemical recurrence of prostate cancer after radical prostatectomy are recorded in approximately 20 to 50% of cases
- Treatment options: salvage radiotherapy (SRT), hormonal therapy, observation
- In patients eligible for SRT, current guidelines recommend **PSMA PET** to exclude distant metastases
- ICAROS, an observational study of our centre, was carried out to evaluate a possible role of MRI before SRT





Radioterapia Oncologica: l'evoluzione al servizio dei pazienti

Methods

- 91 patients were evaluated over a 5-year period
 - Median age: 67 years (range: 41-78)
- Median PSA level at biochemical recurrence: 0.4 ng/ml (IQR: 0.22-1.04)
 - ISUP 3-5 (in 75.8% of patients)





Radioterapia Oncologica: l'evoluzione al servizio dei pazienti

MRI pre-SRT 39% 59%

Results:

■ Local recurrence ■ Pelvic nodal metastases ■ Pelvic bone metastases ■ Negative

BOLOGNA, 27-29 OTTOBRE 2023 PALAZZO DEI CONGRESSI





Radioterapia Oncologica: l'evoluzione al servizio dei pazienti

Results: Site of local recurrence



Bladderneck Vesicourethral anastomosis Rectovesical space Prostatic fossa

BOLOGNA, 27-29 OTTOBRE 2023 PALAZZO DEI CONGRESSI



AIRO2023

Radioterapia Oncologica: l'evoluzione al servizio dei pazienti



Results: Patients with MRI+

PET+ PET- (or with different uptake)





Methods_II

•We compared **two cohorts** of patients screened or not with pre-SRT MRI and matched (case-control) based on:

- PSA before SRT
- Pathological tumour stage
- ISUP grade group
- Pelvic nodal irradiation
- Adjuvant hormonal therapy



AIRO2023

Radioterapia Oncologica: l'evoluzione al servizio dei pazienti

Results_II

- 176 patients included:
 - 88 MRI
 - 88 no MRI

After MRI:

• 61.4% of patients had macroscopic locoregional
relapse → median total dose of SRT: 70.4 Gy
versus 66 Gy

• Higher rate of biochemical relapse-free survival in patients undergoing MRI before SRT:

4-year rates: 74.8% versus 60.7%; p = 0.039







Conclusions

• An unexpectedly high rate of macroscopic local recurrence was recorded by MRI evaluation in our cohort of patients with

biochemical recurrence after prostatectomy. This allowed treatment modulation by delivering a boost to the site of

recurrence, with a significant improvement in the early biochemical outcome.

• These results challenge current recommendations on the most appropriate imaging exams in this clinical setting





Radioterapia Oncologica: l'evoluzione al servizio dei pazienti

Thanks for your Attention!



BOLOGNA, 27-29 OTTOBRE 2023 PALAZZO DEI CONGRESSI

